Remote patient monitoring (RPM) relies on digital health technologies and connected devices to record vital signs and relay data and information to patients, careers, and physicians or healthcare teams. RPM enables clinicians to track patients in real time through a clinician dashboard or directly within a patient’s electronic health record (EHR), allowing timely intervention if necessary. RPM also gives patients more control over their health and a sense of empowerment, while improving health outcomes. The use of RPM has gained significant traction since the beginning of the COVID-19 pandemic in early 2020, with increased demand for alternatives to in-person care as a result of social distancing and lockdown measures. The different types of RPM technologies, such as wearables, mHealth, and telemedicine, have been tapped by the pharmaceutical industry for use across its value chain from drug development through post-marketed strategies.
Wearable devices: Wearable devices are becoming increasingly disease-oriented, as medical devices is one of the fastest growing areas in the life sciences. As such, medical device companies are shifting their interest from consumables to disease/care management services and products. Wearable tech is becoming more advanced, with better battery life and multiple sensors driving more complex and capable devices, accelerated by ever-smarter algorithms powered by artificial intelligence (AI) and machine learning (ML).
mHealth: As part of telehealth, mHealth utilizes mobile technology and smart devices to achieve improved health objectives and outcomes, healthcare services, and research. Increasing network coverage and newer devices and software offer novel opportunities for integration into existing health systems, placing mHealth technologies in a good position to promote quality healthcare. Additionally, mHealth can be applied across clinical research to improve drug discovery and development through to post-market surveillance, as well as directly by consumers.
Telemedicine: Telemedicine became an invaluable tool during the COVID-19 pandemic, allowing patients to connect with and receive care from their HCPs while maintaining safety and minimizing transmission risk. Telemedicine has also been used to mitigate the disruption seen to clinical trials, allowing participants to engage and communicate with investigators and other research staff from the comfort of their own home.
What are the key technology trends impacting the remote patient monitoring market?
Increased interest and activity in RPM solutions: There has been an increase in applications using IoT sensors seeing adoption by hospitals, surgical centers, medical care centers, CROs, and research/diagnostic laboratories. RPM is just one application of IoT sensors in healthcare, and as the population of digitally savvy users who own smartphones and personalized hardware grows, the feasibility of RPM becomes more likely.
Wearables and the collection of health data: Wearable tech in healthcare gives patients the power to track their health at home through things like smartwatches, biometric clothing, e-skin, and biosensors. Currently, the largest market in this space is activity monitors, which is being driven by the sports and fitness segment. However, these devices have expanded significantly within the healthcare market, gaining regulatory approval as medical-grade devices.
Increased availability of mHealth apps: The variety of mHealth tools available to capture patient data is expanding rapidly, as publicly available apps are becoming ubiquitous and a large portion of the population in the US and Europe own smartphones. These mHealth apps offer to help disease management, RPM, and medication adherence across disease indications.
Big Data and AI will continue to dominate as transformational forces in healthcare: The generation of big data enables better monitoring of disease and insights into disease risk prediction and earlier detection, which is especially relevant for neurological conditions that rely on diagnoses that often occur at a late stage when little intervention is possible. Big Data and AI-powered analysis tools can also be used in pharmaceutical research and healthcare service delivery across a spectrum of digital health technologies, and more widely across processes ranging from target identification to commercialization activities. It will eventually reduce R&D cycle time and costs, paving the way to stronger and more sustainable drug pipelines.
Cybersecurity: As the healthcare industry becomes more digitized, there are more avenues for cybercriminals to steal personal and proprietary data, including from medical health records and connected medical devices. Connected devices that collect personal health data, such as wearables, frequently exchange data with paired devices via Bluetooth, which makes them especially susceptible to hacking. Thus, all digital health vendors have recently stepped up their efforts to enforce encryption standards recommended by the Bluetooth Special Interest Group. There is a competing need for enhanced cybersecurity for large healthcare companies and smaller digital health players to ensure cybersecurity and patient safety risks are taken into consideration.
What is the value chain for remote patient monitoring market?
The RPM can be adopted across the entire pharma value chain to various ends. For example, mHealth, wearables, RPM, and telemedicine impact most of the pharma value chain from drug discovery and development, drug approval, and post approval, all the way through to sales and marketing, as well as directly to patients.
The remote monitoring technologies can be used across the pharma value chain:
- Drug discovery and development
- Drug approval & post approval
- Manufacturing & supply chain
- Sales & marketing
Which are key companies in the remote patient monitoring market?
Key companies in the remote patient monitoring are AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Biogen, BMS, Eli Lilly, Gilead, GSK, J&J, Merck & Co., Novartis and Novo Nordisk.
Market report scope
|Key companies||AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Biogen, BMS, Eli Lilly, Gilead, GSK, J&J, Merck & Co., Novartis and Novo Nordisk|
- Key players in the RPM space, with a focus on technology providers and pharma adopters where applicable. The report focuses on any remote monitoring technologies that big pharma has integrated into RPM projects and solutions.
- Thematic briefing which explores different types of RPM in more detail, including wearables, portable devices, mHealth, and telemedicine.
- Key trends impacting the RPM space. Industry trends include the impact of COVID-19 on clinical trials and digital health innovation, how RPM is driving value-based care and increased patient empowerment, and the impact of increased burden of chronic diseases. Technology trends include the role of wearable technology, mHealth, telemedicine, Big Data and artificial intelligence (AI), and cybersecurity. Regulatory trends include the lack of regulatory frameworks for virtual trials and guidelines issues during COVID-19 to support continuation of clinical research.
- Opportunities and challenges for pharma: Opportunities include such changing regulations, continued acceptance of digital technologies, increased collaborations, patient support programs, and value-based care. Challenges include data privacy and security, interoperability, design challenges, and skills shortages.
- Value chain looking at how RPM can be used across the pharma value chain, from drug discovery and development, post drug approval, sales and marketing, and patient use.
- Industry analysis with an analysis of virtual trials including those generating real-world evidence, use of telemedicine during the pandemic, analysis of mobile apps from pharma, as well comprehensive deals, jobs, and Influencer analyses. This section also includes case studies and survey and poll data.
- Profiles of private and public companies in the RPM space.
Reasons to Buy
- Assess who the leading technology players are in the RPM space, as well as leading pharma adopters.
- See examples of how pharma companies are integrating remote monitoring technologies into their value chains.
- Understand what trends are driving the use of RPM, and also what opportunities and challenges exist for pharma in the space.
- See how the RPM landscape is evolving, with a review of company activity including mergers and acquisitions (M&A), strategic partnerships and funding deals, as well as a jobs analysis.
- Assess the impact of COVID-19 on the use of remote monitoring technologies by physicians.
Johnson & Johnson, Pfizer, Roche, Novartis, Takeda, AbbVie, AstraZeneca, Sanofi, GlaxoSmithKline, Eli Lilly, AliveCor, Empatica, Livongo, Omron, Teladoc, Amwell, Aural Analytics, Evidation, Huma, Science37, Medable, THREAD, AiCure, Akili, Babylon, Biobeat, Qardio, Biofourmis, Thirty Madison, Doctolib, Lightship, Studies&Me
Table of Contents
• Healthcare Trends
• Technology Trends
• Regulatory trends
• Macroeconomic Trends
Opportunities and Challenges for Pharma
• Drug Discovery and Development
• Post Drug Approval
• Sales and Marketing
• End Users
• Virtual Clinical Trials Analysis
• Use of RPM-Derived Real-World Evidence in Post-Marketing Studies
• Increased Use of Telemedicine During the COVID-19 Pandemic
• Analysis of Mobile Apps from Pharma
• Analysis of RPM-Related Jobs in Pharma
• Physician Trends in Remote Monitoring Technologies and the Impact of COVID-19 on Usage
• Deals Analysis
o Mergers and Acquisitions
o Strategic Partnerships
o Funding Deals
• Pharma Case Studies
o Genentech Telemedicine-Based Patient Support Programs
o Evidation and Merck: Digital Monitoring with Focus on Alzheimer’s Disease
o Biobeat Collaborates with Amwell and Amgen to Offer Comprehensive Wearable RPM Services
o Roche Leads the Biopharmaceutical Industry in Terms of Digital Biomarker Research and Investment
• Jobs Analysis
• Healthcare Industry Polls
• Social Media Influencers
• Public Pharma Companies
• Private Pharma Companies
• Public Technology Companies
• Private Technology Companies
• Further Reading
o Related Reports
• About the Authors
• Our Thematic Research Methodology
• About GlobalData
• Contact Us
List of Tables
Table 1: Healthcare Trends in the RPM Space
Table 2: Technology Trends in the RPM Space
Table 3: Regulatory Trends in the RPM Space
Table 4: Macroeconomic Trends in the RPM Space
Table 5: Examples of Pharma Companies Utilizing Digital Biomarkers in Drug Development
Table 6: Examples of Pharma Companies Using Virtual Trials
Table 7: Examples of Telemedicine Players in the US and Europe
Table 8: Examples of Pharma Mobile Apps for Patients
Table 9: Examples of M&A in the RPM Space, 2018–2021
Table 10: Examples of Strategic Partnerships in the RPM Space
Table 11: Biopharmaceutical Industry Partnerships Related to RPM
Table 12: Examples of Large Funding Deals in the RPM Space Since Q1 2020
Table 13: Examples of Public Pharma and MedTech Companies in the RPM Space
Table 14: Examples of Private Pharma Companies in the RPM Space
Table 15: Examples of Public Technology Companies in the RPM Space
Table 16: Examples of Private Technology Companies in the RPM Space
List of Figures
Figure 1: Who Are the Leading Players in the RPM Space?
Figure 2: Where Remote Monitoring Technologies Can Be Used Across the Pharma Value Chain
Figure 3: Examples of Companies Developing and Utilizing Digital Biomarkers
Figure 4: Examples of Companies Providing and Utilizing Virtual Trial Platforms
Figure 5: Examples of Companies in the Telemedicine Space
Figure 6: The Proportion of Trials Utilizing Virtual or Digital Components Has Increased Steadily Since 2004
Figure 7: eDiary Is the Most Common Type of Virtual or Digital Component Used in Trials
Figure 8: Metabolic Disorders Is the Leading Therapy Area for Trials Utilizing Virtual or Digital Components
Figure 9: Top 10 Pharma Sponsors of Trials with Virtual or Digital Components
Figure 10: Top Pharma Sponsors or Collaborators of Virtual Trials With RWE Element
Figure 11: Metabolic Disorders Is the Leading Therapy Area for Virtual Trials Related to RWE
Figure 12: Monthly Downloads and Retention for Leading Telemedicine Apps for Patients since January 2020
Figure 13: Assessment of Pharma Activity in the mHealth Space
Figure 14: Trends in RPM-Related Job Posting By Pharma, 2019 – 2021
Figure 15: Examples of Leading Pharma Companies Posting Jobs Related to RPM
Figure 16: Breakdown of RPM Jobs By Type and By Company
Figure 17: Telemedicine and Wearable Devices Used Commonly By Physicians to Monitor Patients Remotely
Figure 18: Preference for In-Person Care is a Leading Patient Barrier to Using Remote Monitoring Technologies
Figure 19: Patients With Chronic Diseases Most Likely to Use Remote Monitoring Technologies
Figure 20: Increased Use of Telemedicine and Wearable Devices By Physicians During the COVID-19 Pandemic
Figure 21: BioBeat Wearable Wristwatch and Patch
Figure 22: Roche’s Floodlight App Contains Tests That Measure Brain Function, Hand Function, and Mobility
Figure 23: Industry Perspective on Where RPM Best Supports the Pharma Value Chain
Figure 24: Main Benefit of Pharma Integrating RPM and Digital Tools into Trials
Figure 25: Barriers to Adopting Software-enabled Practices in Clinical Trials
Figure 26: Design Challenges When Considering RPM Technologies/ Devices
Figure 27: RPM Trends in GlobalData’s Digital Pharma Influencer Database, August 2020 to August 2021
Figure 28: Examples of Top Posts Related to RPM, 2020–2021
Figure 29: Our Five-Step Approach for Generating a Sector Scorecard
Frequently Asked Questions
Key companies in the remote patient monitoring market are AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Biogen, BMS, Eli Lilly, Gilead, GSK, J&J, Merck & Co., Novartis and Novo Nordisk.
The different types of RPM technologies are wearables, mHealth, and telemedicine.
Tel +44 (0) 20 7947 2960
Personal and transaction information are kept safe from unauthorised use.